Synergistic effect of oxytetracycline as a combination treatment with Carboplatin on MCF-7 breast cancer cell line

Authors

  • Eman Jawad Jabber University of Kerbala, College of Veterinary Medicine, Kerbala, Iraq
  • Asawer Mhammed Alzayd University of Kerbala, College of Veterinary Medicine, Kerbala, Iraq
  • Mohammed Jasim Jawad University of Kerbala, College of Veterinary Medicine, Kerbala, Iraq https://orcid.org/0000-0002-6096-945X
  • Ihsan Mohammed Sulbi University of Kerbala, College of Veterinary Medicine, Kerbala, Iraq
  • Saif Mohammed Hassan Al-Zahrawi University College, Department of Pharmacy, Karbala, Iraq
  • Mahmood Jasim Jawad Al-Zahrawi University College, Department of Pharmacy, Karbala, Iraq
  • Adnan Mansour Jasim Al-Qasim Green University, Veterinary Medicine College, Physiology Pharmacology and Biochemistry Department, Babylon, Iraq

DOI:

https://doi.org/10.11606/issn.1678-4456.bjvras.2022.191527

Keywords:

Carboplatin, Oxytetracycline, Breast cancer cells (MCF-7), In vitro assay, Chemotherapy

Abstract

In breast cancer treatment, chemotherapy resistance is a major problem where many receptive tumors rebound and develop resistance. When provided in combination, cancer drugs are most successful, thus reducing the risk of developing resistant cancer cells. However, the evaluation of combination therapies has increased rapidly in recent years. Consequently, by repurposing old treatments, the discovery of additional medicines that may interact synergistically with chemotherapy is considered a current medical aim through discovering a new cancer medication or therapeutic strategy. The purpose of this research is to increase the anti-cancer activity of carboplatin (CP) by increasing the apoptotic effect of breast cancer cells (MCF-7) during in vitro experiments in combination with oxytetracycline. Our results showed a high synergistic effect between oxytetracycline and carboplatin, MCF-7 representative cell treated with carboplatin with/without different concentrations of oxytetracycline (5% and 10% of IC50). Oxytetracycline, which potentiated the action of carboplatin and/or had notable activity was reported as a single agent. This research demonstrated the synergistic relationship between oxytetracycline and carboplatin in viability assays. Surprisingly, our findings suggest that inhibiting treatment strategies can extend carboplatin’s therapeutic window, potentially allowing for cancer therapy.

Downloads

Download data is not yet available.

References

Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AHH, Mohammed OY, Elhassan GO, Harguindey S, Reshkin SJ, Ibrahim ME, Rauch C. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15:71. https://doi.org/10.1186/s12935-015-0221-1. PMID: 26180516.

Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology: patient and health systems opportunities. Nat Rev Clin Oncol. 2015;12(12):732-42. https://doi.org/10.1038/nrclinonc.2015.169. PMid:26483297.

Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanotechnol. 2019;7(1):3-23. https://doi.org/10.2174/2211738507666190122111224. PMid:30666921.

Gray R, Bradley R, Braybrooke J, Liu Z, Peto R, Davies L, Dodwell D, McGale P, Pan H, Taylor C, Barlow W, Bliss J, Bruzzi P, Cameron D, Fountzilas G, Loibl S, Mackey J, Martin M, Del Mastro L, Möbus V, Nekljudova V, De Placido S, Swain S, Untch M, Pritchard KI, Bergh J, Norton L, Boddington C, Burrett J, Clarke M, Davies C, Duane F, Evans V, Gettins L, Godwin J, Hills R, James S, Liu H, MacKinnon E, Mannu G, McHugh T, Morris P, Read S, Wang Y, Wang Z, Fasching P, Harbeck N, Piedbois P, Gnant M, Steger G, Di Leo A, Dolci S, Francis P, Larsimont D, Nogaret JM, Philippson C, Piccart M, Linn S, Peer P, Tjan-Heijnen V, Vliek S, Mackey J, Slamon D, Bartlett J, Bramwell VH, Chen B, Chia S, Gelmon K, Goss P, Levine M, Parulekar W, Pater J, Rakovitch E, Shepherd L, Tu D, Whelan T, Berry D, Broadwater G, Cirrincione C, Muss H, Weiss R, Shan Y, Shao YF, Wang X, Xu B, Zhao D-B, Bartelink H, Bijker N, Bogaerts J, Cardoso F, Cufer T, Julien J-P, Poortmans P, Rutgers E, van de Velde C, Carrasco E, Segui MA, Blohmer JU, Costa S, Gerber B, Jackisch C, von Minckwitz G, Giuliano M, De Laurentiis M, Bamia C, Koliou G-A, Mavroudis D, A’Hern R, Ellis P, Kilburn L, Morden J, Yarnold J, Sadoon M, Tulusan AH, Anderson S, Bass G, Costantino J, Dignam J, Fisher B, Geyer C, Mamounas EP, Paik S, Redmond C, Wickerham DL, Venturini M, Bighin C, Pastorino S, Pronzato P, Sertoli MR, Foukakis T, Albain K, Arriagada R, Bergsten Nordström E, Boccardo F, Brain E, Carey L, Coates A, Coleman R, Correa C, Cuzick J, Davidson N, Dowsett M, Ewertz M, Forbes J, Gelber R, Goldhirsch A, Goodwin P, Hayes D, Hill C, Ingle J, Jagsi R, Janni W, Mukai H, Ohashi Y, Pierce L, Raina V, Ravdin P, Rea D, Regan M, Robertson J, Sparano J, Tutt A, Viale G, Wilcken N, Wolmark N, Wood W, Zambetti M. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393(10179):1440-52. https://doi.org/10.1016/S0140-6736(18)33137-4. PMid:30739743.

Hopkins, AL. Predicting promiscuity: a fossil record for exoplanets, News & Views. 2009; 462(112): 167-168.

Jawad MJ. Translational studies to support the use of pitavastatin as a cancer therapeutic [thesis]. Reino Unido: Keele University; 2020.

Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114:108800. https://doi.org/10.1016/j.biopha.2019.108800. PMid:30921705.

Jin KT, Lu ZB, Chen JY, Liu YY, Lan HR, Dong HY, Yang F, Zhao YY, Chen XY. Recent trends in nanocarrier-based targeted chemotherapy: selective delivery of anticancer drugs for effective lung, colon, cervical, and breast cancer treatment. J Nanomater. 2020;2020:1-14. https://doi.org/10.1155/2020/9184284.

Koltai T. Tetracyclines against cancer: a review In: RESEARCH Gate. Berlin: 2015. 29 p. https://doi.org/10.13140/RG.2.1.4097.1600.

Montemagno C, Pagès G. Metastatic heterogeneity of breast cancer: companion and theranostic approach in nuclear medicine. Cancers (Basel). 2020;12(4):821. https://doi.org/10.3390/cancers12040821. PMid:32235331.

Narayan RS, Molenaar P, Teng J, Cornelissen FMG, Roelofs I, Menezes R, Dik R, Lagerweij T, Broersma Y, Petersen N, Marin Soto JA, Brands E, van Kuiken P, Lecca MC, Lenos KJ, In ’t Veld SGJG, van Wieringen W, Lang FF, Sulman E, Verhaak R, Baumert BG, Stalpers LJA, Vermeulen L, Watts C, Bailey D, Slotman BJ, Versteeg R, Noske D, Sminia P, Tannous BA, Wurdinger T, Koster J, Westerman BA. A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities. Nat Commun. 2020;11:2935. https://doi.org/10.1038/s41467-020-16735-2. PMid:32523045.

Nowak-Sliwinska P, Scapozza L, Ruiz i Altaba A. Drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim Biophys Acta Rev Cancer. 2019;1871(2):434-54.

Rudrapal M, Khairnar JS, Jadhav AG. Drug repurposing (DR): an emerging approach in drug discovery. In: Badria FA, editor. Drug repurposing: hypothesis, molecular aspects and therapeutic applications. London: IntechOpen; 2020.

Sousa GFD, Wlodarczyk SR, Monteiro G. Carboplatin: molecular mechanisms of action associated with chemoresistance. Braz J Pharm Sci. 2014;50(4):693-701. https://doi.org/10.1590/S1984-82502014000400004.

Ulukaya E, Colakogullari M, Wood EJ. Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay. Chemotherapy. 2004;50(1):43-50. https://doi.org/10.1159/000077285. PMid:15084806.

Van den Bogert C, Kroon AM. Effects of oxytetracycline on in vivo proliferation and differentiation of erythroid and lymphoid cells in the rat. Clin Exp Immunol. 1982;50(2):327-35. PMid:7151329.

Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299-309. https://doi.org/10.1038/s41586-019-1730-1. PMid:31723286.

Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141-60. PMid:34322663.

Yadav V, Talwar P. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: an underestimated truth. Biomed Pharmacother. 2019;111:934-46. https://doi.org/10.1016/j.biopha.2018.12.119. PMid:30841473.

Younus ZM. Design and fabrication of hydrogel scaffolds for osteochondral tissue regeneration [thesis]. Reino Unido: Keele University; 2019.

Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y, Huang C. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020;5(1):113. https://doi.org/10.1038/s41392-020-00213-8. PMid:32616710.

Downloads

Published

2022-10-20

Issue

Vol. 59 (2022)

Section

FULL ARTICLE

License

Copyright (c) 2022 Brazilian Journal of Veterinary Research and Animal Science

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The journal content is authorized under the Creative Commons  BY-NC-SA  license (summary of the license: https://creativecommons.org/licenses/by-nc-sa/4.0 | full text of the license: https://creativecommons.org/licenses/by-nc-sa/4.0/legalcode) 

How to Cite

1.
Jabber EJ, Alzayd AM, Jawad MJ, Sulbi IM, Hassan SM, Jawad MJ, et al. Synergistic effect of oxytetracycline as a combination treatment with Carboplatin on MCF-7 breast cancer cell line. Braz. J. Vet. Res. Anim. Sci. [Internet]. 2022 Oct. 20 [cited 2024 Apr. 26];59:e191527. Available from: https://www.revistas.usp.br/bjvras/article/view/191527